Mary Cifaldi

1.5k total citations
30 papers, 1.2k citations indexed

About

Mary Cifaldi is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Mary Cifaldi has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Rheumatology, 11 papers in Hematology and 10 papers in Immunology. Recurrent topics in Mary Cifaldi's work include Rheumatoid Arthritis Research and Therapies (23 papers), Autoimmune and Inflammatory Disorders Research (11 papers) and Systemic Lupus Erythematosus Research (9 papers). Mary Cifaldi is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (23 papers), Autoimmune and Inflammatory Disorders Research (11 papers) and Systemic Lupus Erythematosus Research (9 papers). Mary Cifaldi collaborates with scholars based in United States, United Kingdom and Sweden. Mary Cifaldi's co-authors include Howard G. Birnbaum, Naijun Chen, Sumati Rao, Crystal Pike, Rebecca Kaufman, Yohanne Kidolezi, Adrian R. Levy, Shelagh M. Szabo, Walter P. Maksymowych and Arijit Ganguli and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Clinical Therapeutics.

In The Last Decade

Mary Cifaldi

30 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary Cifaldi United States	20	883	342	311	119	86	30	1.2k
Carolyn Neville Canada	20	961 1.1×	362 1.1×	311 1.0×	89 0.7×	197 2.3×	40	1.3k
Bindee Kuriya Canada	20	737 0.8×	237 0.7×	168 0.5×	96 0.8×	122 1.4×	50	1.1k
Blanca Hernández‐Cruz Spain	17	718 0.8×	275 0.8×	263 0.8×	75 0.6×	89 1.0×	53	955
Ivânio Alves Pereira Brazil	21	800 0.9×	225 0.7×	350 1.1×	129 1.1×	171 2.0×	103	1.3k
Alfred Cividino Canada	19	833 0.9×	231 0.7×	270 0.9×	84 0.7×	206 2.4×	33	1.5k
A. Stirling United Kingdom	10	1.3k 1.4×	219 0.6×	556 1.8×	238 2.0×	199 2.3×	14	1.5k
Siegfried Wassenberg Germany	21	1.8k 2.1×	716 2.1×	726 2.3×	186 1.6×	173 2.0×	61	2.2k
Wouter H Bos Netherlands	20	1.2k 1.3×	202 0.6×	321 1.0×	133 1.1×	131 1.5×	39	1.4k
Jakub Závada Czechia	19	481 0.5×	306 0.9×	103 0.3×	62 0.5×	108 1.3×	59	1.2k
John Londoño Colombia	19	653 0.7×	266 0.8×	228 0.7×	28 0.2×	66 0.8×	116	1.1k

Countries citing papers authored by Mary Cifaldi

Since Specialization

Citations

This map shows the geographic impact of Mary Cifaldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Cifaldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Cifaldi more than expected).

Fields of papers citing papers by Mary Cifaldi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Cifaldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Cifaldi. The network helps show where Mary Cifaldi may publish in the future.

Co-authorship network of co-authors of Mary Cifaldi

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Cifaldi. A scholar is included among the top collaborators of Mary Cifaldi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Cifaldi. Mary Cifaldi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmier, Jordana K., Nancy A. Nickman, Michael T. Halpern, et al.. (2017). Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. Clinical Therapeutics. 39(8). 1600–1617. 24 indexed citations

Revicki, Dennis A., Arijit Ganguli, Miriam Kimel, et al.. (2015). Reliability and Validity of the Work Instability Scale for Rheumatoid Arthritis. Value in Health. 18(8). 1008–1015. 12 indexed citations

Başer, Onur, Arijit Ganguli, Sanjoy Roy, Lin Xie, & Mary Cifaldi. (2015). Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis. Clinical Therapeutics. 37(7). 1454–1465. 25 indexed citations

Rasu, Rafia S., et al.. (2014). Impact of JIA on parents’ work absences. Lara D. Veeken. 54(7). 1177–1185. 4 indexed citations

Neubauer, Stefan, et al.. (2014). Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. Health Economics Review. 4(1). 32–32. 31 indexed citations

Kleinman, Nathan L., Mary Cifaldi, James E. Smeeding, James W. Shaw, & Richard A. Brook. (2013). Annual Incremental Health Benefit Costs and Absenteeism Among Employees With and Without Rheumatoid Arthritis. Journal of Occupational and Environmental Medicine. 55(3). 240–244. 25 indexed citations

Liu, Yifei, Eric Q. Wu, Arielle G. Bensimon, et al.. (2012). Cost Per Responder Associated with Biologic Therapies for Crohn’s Disease, Psoriasis, and Rheumatoid Arthritis. Advances in Therapy. 29(7). 620–634. 55 indexed citations

Smolen, Josef S, Désirée van der Heijde, Edward Keystone, et al.. (2012). Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Annals of the Rheumatic Diseases. 72(7). 1156–1162. 55 indexed citations

Birnbaum, Howard G., Crystal Pike, Ritesh Banerjee, Tracy Waldman, & Mary Cifaldi. (2012). Changes in Utilization and Costs for Patients with Rheumatoid Arthritis, 1997 to 2006. PharmacoEconomics. 30(4). 323–336. 17 indexed citations

10.

Wong, Bruce, et al.. (2011). Analysis of Drug and Administrative Costs Allowed by U.S. Private and Public Third-Party Payers for 3 Intravenous Biologic Agents for Rheumatoid Arthritis. Journal of Managed Care Pharmacy. 17(4). 313–320. 18 indexed citations

11.

Szabo, Shelagh M., Adrian R. Levy, Sumati Rao, et al.. (2011). Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: A population‐based study. Arthritis & Rheumatism. 63(11). 3294–3304. 154 indexed citations

12.

Strand, Vibeke, Anne M. Rentz, Mary Cifaldi, et al.. (2011). Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study. The Journal of Rheumatology. 39(1). 63–72. 58 indexed citations

13.

Vollenhoven, Ronald van, Mary Cifaldi, Saurabh Ray, Naijun Chen, & Michael H. Weisman. (2010). Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: Work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care & Research. 62(2). 226–234. 53 indexed citations

14.

Birnbaum, Howard G., Lizheng Shi, Crystal Pike, et al.. (2009). Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature. Expert Opinion on Pharmacotherapy. 10(2). 255–269. 14 indexed citations

15.

Birnbaum, Howard G., Crystal Pike, Rebecca Kaufman, & Mary Cifaldi. (2009). Employer Model of Workplace Impacts of Anti-TNF Therapy for Rheumatoid Arthritis. Journal of Occupational and Environmental Medicine. 51(10). 1167–1176. 6 indexed citations

16.

Davies, Andrew, Mary Cifaldi, Oscar G. Segurado, & Michael H. Weisman. (2008). Cost-Effectiveness of Sequential Therapy with Tumor Necrosis Factor Antagonists in Early Rheumatoid Arthritis. The Journal of Rheumatology. 36(1). 16–26. 39 indexed citations

17.

Wu, Eric Q., et al.. (2007). Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Current Medical Research and Opinion. 23(8). 1749–1759. 33 indexed citations

18.

Mittendorf, Thomas, et al.. (2007). Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis.. PubMed. 34(12). 2343–50. 29 indexed citations

19.

Block, Stan L., Mary Cifaldi, Yihua Gu, & Maria Paris. (2005). A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: A multicenter, prospective, single-blind study. Clinical Therapeutics. 27(6). 786–794. 16 indexed citations

20.

Cifaldi, Mary, et al.. (2004). Parent-Reported Outcomes for Treatment of Acute Otitis Media with Cefdinir or Amoxicillin/Clavulanate Oral Suspensions. Pediatric Drugs. 6(6). 387–393. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact